| Machine learning, Natural Language Processing |
2025. 02 - |
Development of machine translation models specialized in translating regulatory for pharmaceuticals and related products |
Ongoing |
| RWD/RWE |
2025.02 - |
Real world effectiveness of GLP-1RA in reducing the risk of non-alcoholic fatty liver disease in type 2 diabetes patients |
Ongoing |
| Machine learning |
2024.08 - |
Prediction of drug-drug interaction in humans using large language models |
Ongoing |
| Machine learning, Natural Language Processing |
2023.03 - |
Improving Generalization Performance of Natural Language Processing Models to Extract Drug Safety Information from Multi-institutional Clinical Notes |
Ongoing |
| RWD/RWE, Machine learning |
2022.12 -2023.12 |
Improved prediction of acute coronary syndrome by replacing binary categorical variables with propensity scores in patients with type 2 diabetes mellitus |
Completed |
| Clinical Pharmacology |
2022.12 - |
An analysis of clinical trial designs for COVID-19 therapeutics development in Korea and suggestions for improvement |
Ongoing |
| RWD/RWE |
2022.11 - 2024.03 |
A real-world data-based retrospective observational study to evaluate effectiveness and safety of steroid pretreatment prior to remission induction chemotherapy in patients with pediatric acute lymphoblastic leukemia |
Completed |
| RWD/RWE, Machine learning |
2022.08 - |
Drug repurposing framework based on crossover clinical trials emulated by using electronic health records and Bayesian Additive Regression Tree (BART) |
Ongoing |
| RWD/RWE |
2022.07 - 2024.02 |
Trajectory of clinical features in Korean COVID-19 patients: an observational study based on real-world data |
Completed |
| Clinical Pharmacology, Regulatory Science |
2022.07 - 2024.02 |
Country Contribution of Investigators to Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration |
Completed |
| Machine learning |
2022.07 - 2023.12 |
Comparison of artificial intelligence and pharmacometric models for predicting plasma concentrations of antiepileptic drugs based on therapeutic drug monitoring records |
Completed |
| Machine learning |
2022.05 - 2023.04 |
Joint research with Microsoft Research Asia (MSRA): Revisiting and reformulating machine learning-based drug repositioning using clinical trials database and eligibility criteria information |
Completed |
HOME
